PD-L1 inhibitor has been reported a promising respond in non-small cell lung cancer, melanoma, renal cell carcinoma and head and neck cancers [29], however, the response of PD-L1 inhibitor in HCC is still controversial [30]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.